Literature DB >> 17403204

JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis.

S Regina, O Herault, L D'Alteroche, C Binet, Y Gruel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17403204     DOI： 10.1111/j.1538-7836.2007.02384.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  7 in total

1.  Venous thromboembolic disease.

Authors:  Michael B Streiff; Paula L Bockenstedt; Spero R Cataland; Carolyn Chesney; Charles Eby; John Fanikos; Patrick F Fogarty; Shuwei Gao; Julio Garcia-Aguilar; Samuel Z Goldhaber; Hani Hassoun; Paul Hendrie; Bjorn Holmstrom; Kimberly A Jones; Nicole Kuderer; Jason T Lee; Michael M Millenson; Anne T Neff; Thomas L Ortel; Judy L Smith; Gary C Yee; Anaadriana Zakarija
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

2.  JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.

Authors:  Amandeep Salhotra; Thein H Oo
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-18       Impact factor: 0.900

3.  JAK2V617F mutation in patients with splanchnic vein thrombosis.

Authors:  Sandra Guerra Xavier; Telma Gadelha; Glicínia Pimenta; Angela Maria Eugenio; Daniel Dias Ribeiro; Fernanda Mendes Gomes; Martin Bonamino; Ilana Renault Zalcberg; Nelson Spector
Journal:  Dig Dis Sci       Date:  2009-08-19       Impact factor: 3.199

4.  Initial management of noncirrhotic splanchnic vein thrombosis: when is anticoagulation enough?

Authors:  Pranavi Ravichandran; Kris P Croome; Michael J Kovacs; Alejandro Lazo-Langner; Roberto Hernandez-Alejandro
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04

5.  The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

Authors:  Ipek Yonal; Binnur Pinarbası; Fehmi Hindilerden; Veysel Sabri Hancer; Meliha Nalcaci; Sabahattin Kaymakoglu; Reyhan Diz-Kucukkaya
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

6.  Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg.

Authors:  Mandy N Lauw; Erik W N Bus; Alexander F Y van Wulfften Palthe; Michiel Coppens; Christa H Homburg; Saskia Middeldorp; C Ellen van der Schoot; Harry R Koene; Bart J Biemond
Journal:  Ann Hematol       Date:  2011-04-12       Impact factor: 3.673

7.  The Natural History, Treatments, and Outcomes of Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease.

Authors:  Leonard Naymagon; Douglas Tremblay; Nicole Zubizarreta; Erin Moshier; Steven Naymagon; John Mascarenhas; Thomas Schiano
Journal:  Inflamm Bowel Dis       Date:  2021-01-19       Impact factor: 5.325
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.